Skip to Content

'
Michelle A.T. Hildebrandt, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007 Mayo Clinic College of Medicine, Rochester, MN, PHD, Molecular Pharmacology and Experimental Therapeutics, Mentor: Richard Weinshilboum, M.D.
2001 University of Wisconsin-River Falls, River Falls, WI, BS, Biology

Postgraduate Training

2007-2009 Research Fellowship, Cancer Prevention Research Training Program, Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mentor: Xifeng Wu, M.D., Ph.D.
2005 Short Course in Medical and Experimental Mammalian Genetics, The Jackson Laboratory, Bar Harbor, ME

Experience/Service

Academic Appointments

Instructor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-5/2012

Honors and Awards

2012 Highly Rated Poster Presentation, AACR Annual Meeting
2012 Leading Mentor in Cancer Prevention Award - Honorable Mention, MD Anderson Division of Cancer Prevention and Population Sciences
2009 American Association for Cancer Research Scholar-in-Training Award, funded by Susan G. Komen for the Cure, AACR - Frontiers in Cancer Prevention Research Meeting
2009 Bayer HealthCare Pharmaceuticals, Inc. Award for Postgraduate Population/Patient-Oriented Research, MD Anderson Cancer Center Trainee Research Day
2009 MD Anderson Trainee Excellence Award, MD Anderson Cancer Center
2009 Trainee of the Quarter Award, MD Anderson Cancer Center
2008 Bayer HealthCare Pharmaceuticals, Inc. Award for Postgraduate Population/Patient-Oriented Research and Winner of Poster Presentation Competition, MD Anderson Cancer Center Trainee Research Day
2007-2009 Cancer Prevention Training Program Fellowship, NCI/MD Anderson Cancer Center
2005 Mayo Graduate School Travel Award, Mayo Clinic College of Medicine
2005 Top Abstract, American Society of Clinical Pharmacology and Therapeutics Annual Meeting
2000 Summer Student Training Program, The Jackson Laboratory

Selected Publications

Peer-Reviewed Original Research Articles
1. Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA (co-first author), Kratz C, Bishop DT, Casey G, Cook MB, Erickson RL, Fossa SD, Gjessing HK, Greene MH, Jacobs KB, Kanetsky PA, Kolonel LN, Korde LA, LeMarchand L, Lewinger JP, Lothe RA, Pike MC, Rahman N, Rubertone MV, Schwartz SM, Siegmund KD, Skinner EC, Thomas DC, Turnbull C, Van Den Berg DJ, Wu X, Yeager M, Nathanson KL, Chanock SJ, Cortessis VK, McGlynn KA. A meta-analysis of genome-wide association studies to identify testicular germ cell tumor susceptibility loci. Hum Mol Genet. In Press.
2. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KY, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). In Press.
3. Ke HL, Chen M, Ye Y, Hildebrandt MA, Wu WJ, Wei H, Huang M, Chang DW, Dinney CP, Wu X. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. e-Pub 2/2013. PMID: 23322153.
4. Pu X, Roth JA, Hildebrandt MA, Ye Y, Wei H, Minna JD, Lippman SM, Wu X. MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients. Cancer Res. e-Pub 2/2013. PMID: 23378343.
5. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res 18(21):5983-91, 11/2012. e-Pub 9/2012. PMID: 22977190.
6. Kim JY, Hildebrandt MA (co-first author), Pu X, Ye Y, Correa AM, Vaporciyan AA, Wu X, Roth JA. Variations in the Vascular Endothelial Growth Factor Pathway Predict Pulmonary Complications. Ann Thorac Surg 94(4):1079-85, 10/2012. e-Pub 7/2012. PMCID: PMC3466075.
7. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18(14):3982-91, 7/2012. e-Pub 6/2012. PMID: 22661538.
8. Hildebrandt MA, Lippman SM, Etzel CJ, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Genetic variants in the PI3K/PTEN/AKT/MTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18(13):3705-13, 7/2012. e-Pub 5/2012. PMCID: PMC3404728.
9. Hildebrandt MA (corresponding author), Tan W, Tamboli P, Huang M, Ye Y, Lin J, Lee JS, Wood CG, Wu X. Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis 33(4):799-803, 4/2012. e-Pub 1/2012. PMCID: PMC3324439.
10. Wei H, Ke HL, Lin J, Shete S, Wood CG, Hildebrandt MA. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk. Mol Carcinog. e-Pub 4/2012. PMCID: PMC3424388.
11. Wu X, Scelo G, Purdue MP, Rothman N, Johansson M, Ye Y, Wang Z, Zelenika D, Moore LE, Wood CG, Prokhortchouk E, Gaborieau V, Jacobs KB, Chow WH, Toro JR, Zaridze D, Lin J, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Jinga V, Bencko V, Slamova A, Holcatova I, Navratilova M, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL, Boeing H, Vineis P, Clavel-Chapelon F, Palli D, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Virtamo J, Vatten L, Hveem K, Fletcher T, Koppova K, Cussenot O, Cancel-Tassin G, Benhamou S, Hildebrandt MA, Pu X, Foglio M, Lechner D, Hutchinson A, Yeager M, Fraumeni JF, Lathrop M, Skryabin KG, McKay JD, Gu J, Brennan P, Chanock SJ. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 21(2):456-62, 1/2012. e-Pub 10/2011. PMCID: PMC3276284.
12. Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J. Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. Cancer 118(1):205-15, 1/2012. e-Pub 6/2011. PMCID: PMC3178723.
13. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS One 7(5):e37891, 2012. e-Pub 5/2012. PMCID: PMC3360659.
14. Yin J, Lu C, Gu J, Lippman SM, Hildebrandt MA, Lin J, Stewart D, Spitz MR, Wu X. Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis 32(12):1867-71, 12/2011. e-Pub 9/2011. PMCID: PMC3220611.
15. Tan W, Hildebrandt MA, Pu X, Huang M, Lin J, Matin SF, Tamboli P, Wood CG, Wu X. Role of inflammatory-related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol 186(5):2071-7, 11/2011. e-Pub 9/2011. PMID: 21944129.
16. Lin M, Stewart DJ, Spitz MR, Hildebrandt MA, Lu C, Lin J, Gu J, Huang M, Lippman SM, Wu X. Genetic variations in the transforming growth factor beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 32(7):1050-6, 7/2011. e-Pub 4/2011. PMCID: PMC3128559.
17. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103(10):817-25, 5/2011. e-Pub 4/2011. PMCID: PMC3096796.
18. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Hong WK, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. Hum Mol Genet 20(4):820-6, 2/2011. e-Pub 11/2010. PMCID: PMC3024041.
19. Lee JJ, Wu X, Hildebrandt MA (second author), Yang H, Khuri FR, Kim E, Gu J, Ye Y, Lotan R, Spitz MR, Hong WK. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4(2):185-93, 2/2011. PMID: 21292633.
20. Pu X, Hildebrandt MA (co-first author), Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71(1):82-8, 1/2011. e-Pub 5/2010. PMCID: PMC2952281.
21. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic Variants in TGF-ß Pathway Are Associated with Ovarian Cancer Risk. PLoS One 6(9):e25559, 2011. e-Pub 9/2011. PMCID: PMC3184159.
22. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA (co-second author), Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42(11):978-84, 11/2010. e-Pub 10/2010. PMCID: PMC3049891.
23. Chen M, Hildebrandt MA (co-first author), Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 3(10):1235-45, 10/2010. e-Pub 9/2010. PMCID: PMC2955764.
24. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29(42):5724-8, 10/2010. e-Pub 8/2010. PMID: 20676129.
25. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387-91, 8/2010. e-Pub 6/2010. PMCID: PMC2915631.
26. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 49(2):183-9, 2/2010. PMID: 19851984.
27. Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):e12402, 2010. e-Pub 8/2010. PMCID: PMC2928273.
28. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27(6):857-71, 2/2009. e-Pub 1/2009. PMCID: PMC2738430.
29. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30(12):2047-52, 2009. PMCID: PMC2792319.
30. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 68(17):7050-8, 9/2008. PMCID: PMC2562356.
31. Yu Z, Wang L, Hildebrandt MA, Schaid DJ. Testing whether genetic variation explains correlation of quantitative measures of gene expression, and application to genetic network analysis. Stat Med 27(19):3847-67, 8/2008. PMCID: PMC2729096.
32. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Brüning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 68(14):5997-6005, 7/2008. PMCID: PMC2518124.
33. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res 68(12):4791-801, 6/2008. PMCID: PMC2490824.
34. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 14(11):3503-13, 6/2008. PMCID: PMC2778274.
35. Moyer AM, Salavaggione OE, Hebbring SJ, Moon I, Hildebrandt MA, Eckloff BW, Schaid DJ, Wieben ED, Weinshilboum RM. Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res 13(23):7207-16, 12/2007. PMID: 18056202.
36. Hildebrandt MA, Carrington DP, Thomae BA, Eckloff BW, Schaid DJ, Yee VC, Weinshilboum RM, Wieben ED. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J 7(2):133-43, 4/2007. e-Pub 6/2006. PMID: 16801938.
37. Schaid DJ, Batzler AJ, Jenkins GD, Hildebrandt MA. Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet 79(6):1071-80, 12/2006. e-Pub 11/2006. PMCID: PMC1698709.
38. Hildebrandt MA, Salavaggione OE, Martin YN, Flynn HC, Jalal S, Wieben ED, Weinshilboum RM. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 321(4):870-8, 9/2004. PMID: 15358107.
39. Thomae BA, Rifki OF, Theobald MA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J Neurochem 87(4):809-19, 11/2003. PMID: 14622112.
40. Tan W, Gu J, Huang M, Wu X, Hildebrandt MA. Aberrant miRNA methylation in tumors from surgically resected lung cancer patients and association with survival. Submitted.
41. Wei H, Hildebrandt MA, Gu J, Ye Y, Huang M, Dinney C, Wu X. Bioinformatics, genome-wide association study, and functional assay identify an insertion/deletion polymorphism in YES1 as a novel bladder cancer susceptibility locus. Submitted.
42. Iverson ES, Weber RP, Concannon PJ, Marks JR, Berchuck A, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Hein A, Ekici AB, Beckman MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Seibold P, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum I, Duerst M, Hillemanns P, Doerk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker C, Modugno F, Edwards RP, Ness RB, Bois A, Heitz F, Schwabb I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Hogdall E, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Veirkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Lin J, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Vitonis AF, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Chandran U, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KKH, Kiemeney LA, Massuger LFAG, Hays LE, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Gronwald K, Lubinski J, Jakibowska A, Krzystolik K, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Baker H, Dicks E, Song H, Tyrer J, Pharoah PP, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Harrington P, Wu AH, Pearce CL, Pike MC, Lee A, Budzilowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Schildkraut JM. Follow-Up of DNA Damage Response and Repair Gene Associations with Epithelial Ovarian Cancer - Evidence that Common Variation in CHEK2 Plays an Etiologic Role. Submitted.
43. Hildebrandt MA, Roth JA, Vaporciyan AA, Pu X, Ye Y, Correa AM, Kim JY, Swisher SG, Wu X. Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Submitted.
44. Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang G-E, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su W-C, Wang W-C, Huang MS, Chang DW, Li Y, Pankratz VS, Yang PC, Minna JD, Hong WK, Hildebrandt MA (co-last author), Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Submitted.
45. Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA (co-first author), Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fossa SD, Jacobs KB, Korde LA, Lothe RA, Loud JT, Rahman N, Rubertone MV, Skinner EC, Thomas DC, Wu X, Yeager M, Schumacher FR, Greene MH, Schwartz SM, McGlynn KA, Chanock SJ, Nathanson KL. Meta-analysis identifies four new loci for testicular germ cell tumor. Submitted.
46. Wang Y, Gu J, Roth JA, Hildebrandt MA, Lippman SM, Ye Y, Minna JD, Wu X. Pathway-based serum microRNA profiling and survival in patients with advanced-stage non-small cell lung cancer. Submitted.

Invited Articles
1. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 28(3-4):269-80, 12/2009. PMID: 20016998.
2. Hildebrandt MA, Ajani JA, Hofstetter W, Swisher S, Wu X. The role of PI3K/PTEN/AKT/mTOR Genetic Variation and Clinical Outcomes following Chemoradiotherapy for Esophageal Cancer. Am J Hemtol Oncol, 9/2009.
3. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5(7):745-55, 7/2009. PMID: 19442035.
4. Hildebrandt M, Adjei A, Weinshilboum R, Johnson JA, Berlin DS, Klein TE, Altman RB. Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenet Genomics 19(6):404-6, 6/2009. PMID: 19451861.

Abstracts
1. Thomae B, Rifki O, Theobald MA, Eckloff B, Wieben E, Weinshilboum R. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: common functional genetic polymorphism in African-American subjects. American Society of Clinical Pharmacology and Experimental Therapeutics Annual Meeting, 2003.
2. Hildebrandt MA, Carrington D, Thomae B, Eckloff B, Schaid D, Yee V, Weinshilboum R, Wieben E. Genetic diversity and function in the human cytosolic sulfotransferases. NIGMS Pharmacogenomics Resarch Network (PGRN) II Scientific Meeting, St. Louis, MO, 2005.
3. Hildebrandt MA, Salavaggione O, Martin,Y, Flynn H, Jalal S, Wieben E Weinshilboum R. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. American Society of Clinical Pharmacology and Experimental Therapeutics Annual Meeting, 2005.
4. Hildebrandt MA, Carrington D, Thomae B, Eckloff B, Schaid D, Yee V, Weinshilboum R, Wieben E. Sulfotransferase pharmacogenomics: gene family sequence variation and functional genomics. 46th Annual Short Course in Experimental and Mammalian Genetics, The Jackson Laboratory, Bar Harbor, ME, 2005.
5. Schaid D, Hildebrandt MA, Weinshilboum R. Scanning for ‘Hot Spot’ SNPs Having a Large Number of Trans-Effects on Quantitative Gene Expressions. 8th International Meeting on Human Genome Variation and Complex Genome Analysis, Hong Kong, 2006.
6. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Hildebrandt MA, Schaid D, Weinshilboum R, Wang L. A genome-wide approach to identify pharmacogenomic candidate genes that contribute to variation in cytosine arabinoside (Ara-C) cytotoxicity. American Society of Human Genetics Annual Meeting, Anaheim, CA, 2007.
7. Hildebrandt MA, Yang H, Hung M-C, Izzo J, Huang M, Ajani J, Wu X. Genetic variation in AKT1 and AKT2 is associated with clinical outcomes following chemotherapy of esophageal cancer. 60th Annual Symposium on Cancer Research - Personalized Risk Assessment and Management, Houston, TX, 2007.
8. Moyer A, Salavaggione O, Hebbring S, Moon I, Hildebrandt MA, Eckloff B, Schaid D, Wieben E, Weinshilboum R. Glutathione S-Transferase T1 and M1 pharmacogenomics. American Society of Clinical Pharmacology and Experimental Therapeutics Annual Meeting, San Diego, CA, 2007.
9. Wang, L., Li L, Fridley B, Kalari K, Batzler A, Jenkins G, Hildebrandt MA, Schaid D. Pharmacogenomics of cytidine analogues: application of a cell-based model system. Cold Spring Harbor Laboratory/Sanger Centre Joint Pharmacogenetics Meeting, Sanger Centre, Hinxton, UK, 2007.
10. Hildebrandt MA, Yang H, Hung M-C, Izzo J, Huang M, Ajani J, Wu X. Genetic variation in AKT1 and AKT2 is associated with clinical outcomes following chemotherapy of esophageal cancer. American Association for Cancer Research Annual Meeting, San Diego, CA, 2008.
11. Chen M, Cassidy A, Gu J, Yang H, Hildebrandt MA, Lin J, Ye Y, Dinney CP, Wu X. Genetic variation in PI3K-AKT-mTOR pathway and urinary bladder cancer risk. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Washington, DC, 2008.
12. Clague J, Lin J, Chang J, Hildebrandt MA, Izzo J, Yang H, Kamat A, Wu X. Genetic variations in Sonic pathway genes as predictors of bladder cancer risk. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Washington, DC, 2008.
13. Moyer A, Sun Z, Jenkins G, Batzler A, Hildebrandt MA, Schaid D, Yang P, Weinshilboum R. Glutathione pathway pharmacogenomics and response to platinum-based chemotherapy of lung cancer. American Society of Clinical Pharmacology and Experimental Therapeutics Annual Meeting, Orlando, FL, 2008.
14. Ji Y, Olson J, Zhang J, Hildebrandt MA, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon M, Brauch H, Eichelbaum M, Justenhove C, Hamann U, Ko Y, Buning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R. Membrane-bound (MB) catechol O-methyltransferase (COMT) genetic polymorphisms: catecholestrogen conjugation and breast cancer risk reduction. American Society of Clinical Pharmacology and Experimental Therapeutics Annual Meeting, Orlando, FL, 2008.
15. Hildebrandt MA, Tamboli P, Huang M, Ye Y, Lee J-S, Wu X. Kinase gene expression profiles are associated with clinical outcomes in clear cell renal cell carcinoma patients. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Washington, DC, 2008.
16. Hildebrandt MA, Komaki R, Chang JY, Liao Z, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. Genetic variants in inflammation pathway genes are associated with the development of radiation-induced toxicity following treatment for non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Denver, CO, 2009.
17. Clague J, Chang J, Hildebrandt MA, Yang H, Lin J, Lu C, Stewart DJ, Wu X. Genetic variation in Sonic hedgehog pathway genes as predictors of survival in patients with non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Denver, CO, 2009.
18. Pu X, Lippman SM, Hildebrandt MA, Chang JY, Lu C, Stewart DJ, Wu X. Genetic variations in genes encoding microRNA processing genes are associated with overall survival in non-small cell lung cancer patients. American Association for Cancer Research Annual Meeting, Denver, CO, 2009.
19. Chen M, Kamat A, Hildebrandt MA, Zhang X, Grossman, HB, Dinney CP, Wu X. Genetic variations in the Sonic hedgehog pathway and clinical outcomes in bladder cancer. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Houston, TX, 2009.
20. Pu X, Lu C, Stewart DJ, Gu J, Hildebrandt MA, Lin J, Lippman SM, Wu X. MicroRNA-related polymorphisms are associated with clinical outcomes in early stage non-small cell lung cancer patients. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Houston, TX, 2009.
21. Hildebrandt MA, Lippman SM, Kim E, Lee JJ, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X. Pharmacogenetics of retinoid chemoprevention in head and neck cancer patients: modulation of response by common genetic variation in the mTOR signaling pathway. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Houston, TX, 2009.
22. Gu J, Ye Y, Spitz MR, Lin J, Kiemeney LA, Xing J, Hildebrandt MA, Hong WK, Amos CI, Wu X. A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity and cancer risk. American Association for Cancer Research Annual Meeting, Washington, D.C. 2010.
23. Yin J, Gu J, Lu C, Chang J, Hildebrandt MA, Spitz MR, Stewart D, Wu X. Genetic variations in the cell-cycle pathway and survival of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy. American Association for Cancer Research Annual Meeting, Washington, D.C. 2010.
24. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hsa-miR-9 expression patterns are associated with metastatic recurrence in patients with clear cell renal cell carcinoma through hypermethylation of the gene in tumor tissue. American Association for Cancer Research Annual Meeting, Washington, D.C. 2010.
25. Lin M, Hildebrandt M, Stewart D, Lippman SM, Lu C, Spitz MR, Wu X. Lung cancer chemotherapy: genetic variations in the transforming growth factor beta pathway as predictors of survival. American Association for Cancer Research Annual Meeting, Washington, D.C. 2010.
26. Tan W, Gu J, Hildebrandt MA, Huang M, Wistuba II, Roth JA, Spitz MR, Wu X. Aberrant MiRNA methylation in tumors from surgically resected lung cancer patients and association with survival. American Association for Cancer Research Annual Meeting, Washington, D.C. 2010.
27. Tan W, Hildebrandt MA, Pu X, Huang M, Tamboli P, Wood CG, Wu X. Role of inflammatory-related gene expression in clear cell renal cell carcinoma. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Philadelphia, PA, 2010.
28. Hildebrandt MA, Roth JA, Vaporciyan AA, Pu X, Ye Y, Correa AM, Kim JY, Swisher SG, Wu X. Genetic variation in the p38 signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. American Association for Cancer Research Annual Meeting, Orlando, FL, 2011.
29. Pu X, Spitz MR, Amos CI, Ye Y, Hildebrandt MA, Chang DW, Lu C, Stewart S, Roth JA, Lippman SM, Christiani D, Wu X. Genetic predictors of clinical outcomes for patients with non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Orlando, FL, 2011.
30. Zhang X, Hildebrandt MA, Horikawa Y, Pu X, Wood CG, Gu J. The expression of RN7SK paralogs in tumors of renal cell carcinoma is associated with patient survival. American Association for Cancer Research Annual Meeting, Orlando, FL, 2011.
31. Hildebrandt MA, Pu X, Lippman SM, Wu X. Mitochondrial DNA copy number is inversely associated with overall survival in non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Chicago, IL, 2012.
32. Wei H, Hildebrandt MA, Gu J, Ye Y, Huang M, Dinney CP, Wu X. A combined bioinformatics and GWAS approach indentifies a functional 3'-UTR insertion/deletion in YES1 associated with bladder cancer risk. American Association for Cancer Research Annual Meeting, Chicago, IL, 2012.
33. Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: A large-scale, two-phase genetic study. American Association for Cancer Research Annual Meeting, Chicago, IL, 2012.
34. Hildebrandt MA, Lin M, Eng C, Kopetz S, He Y, Lin J, Sun W, Hawk E, Wu X. Common, germline genetic variants in the Wnt/beta-catenin signaling pathway and colorectal cancer susceptibility. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Anaheim, CA, 2012.
35. Zhang F, Eng C, Lin M, Hildebrandt MA, He Y, Lin J, Huang M, Gu J, Wu X. Genetic variations in aging related genes/pathways and colorectal cancer risk. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Anaheim, CA, 2012.
36. Pu X, Hildebrandt MA, Kim JY, Ye Y, Vaporciyan AA, Correa AM, Swisher SG, Roth JA, Wu X. Genetic Variations in the JAK-STAT Pathway are Associated with Postoperative Pulmonary Complications after Lobectomy in Lung Cancer Patients. American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, Anaheim, CA, 2012.
37. Chung CC, Zhaoming W, Kanetsky CT, Turnbull C, McGlynn K, Greene MH, Hildebrandt MAT, Skotheim RI, Kratz C, Cook M, Schumacher F, Koster R, Yeager M, Jacobs KB, Schwartz S, Bishop DT, Cortessis V, Rahman N, Wu X, Chanockl SJ, Nathanson KL. Meta-analysis identifies four new loci for testicular germ cell tumor. American Society for Human Genetics Annual Meeting, San Francisco, CA, 2012.

Last updated: 3/8/2013